P3I
CRNX

Progeny 3 Inc’s Crinetics Pharmaceuticals CRNX Stock Holding History

Progeny 3 Inc’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,000
Closed -$872K – 31
2026
Q1 		$872K Hold
24,000
– – 0.05% 32
2025
Q4 		$1.12M Buy
+24,000
New +$1.07M 0.06% 34

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Progeny 3 Inc's CRNX Position: Q2 2026 in Review

Progeny 3 Inc sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 24,000 shares — an estimated $872K sold.

Progeny 3 Inc first reported a position in CRNX in Q4 2025 and held it in 2 quarters. The position peaked at $1.12M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Progeny 3 Inc reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Progeny 3 Inc sold 24,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $872K.
  • Progeny 3 Inc first reported a position in Crinetics Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Progeny 3 Inc's Crinetics Pharmaceuticals position peaked at $1.12M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Progeny 3 Inc's 13F filing for Q2 2026, filed 14 Aug 2026.